Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 25

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 25
---
 PIPE Financing and may                                                             
 decline significantly if the Divestiture or the PIPE Financing is not completed on the terms reflected in the Divestiture Agreement or the Subscription Agreement, or at all; |

| • |     | the fact that under the terms of the Divestiture Agreement, we are restrained from soliciting other acquisition 
 proposals during the pendency of the Divestiture;                                                               |

- 15 -

| • |     | the fact that, if the Divestiture is completed, our stockholders will forgo the opportunity to realize the 
 potential long-term value of the successful execution of our current strategy for the FYARRO Business;     |

| • |     | our dependence on licensing arrangements in the operation of the FYARRO Business and ADC Programs; |

| • |     | our ability to effectively integrate and manage the ADC Programs or realize the expected benefits and synergies 
 from the Divestiture, the License Agreement, the ADC Programs and the PIPE Financing;                           |

| • |     | our ability to achieve the anticipated operational and financial results following the PIPE Financing and the 
 in-license of the ADC Programs;                                                                               |

| • |     | our ability to retain members of management and other key employees following the PIPE Financing and the 
 Divestiture;                                                                                             |

| • |     | our ability to compete with other companies currently marketing or engaged in the development of treatments for 
 the indications that we are pursuing and any other product candidates we may develop in the future;             |

| • |     | our ability to develop, establish and maintain name recognition; |

| • |     | our ability to obtain additional capital or financing when and if necessary, to execute our business plan, 
 including through offerings of debt or equity or sale of any of our assets;                                |

| • |     | our ability to obtain and maintain intellectual property protection and to protect our intellectual property 
 rights;                                                                                                      |

| • |     | the impact of any claim that we have infringed on intellectual property rights of others; |

| • |     | the implementation of our business model and our strategic plans for our business, our strategic plans related to 
 FYARRO and the further development of our ADC Programs and any other product candidates;                          |

| • |     | our ability to contract with and rely on third parties to assist in conducting our preclinical studies, clinical    
 trials and manufacturing of FYARRO, the ADC Programs and any other product candidates we may develop in the future; |

| • |